50
Participants
Start Date
January 7, 2020
Primary Completion Date
April 27, 2023
Study Completion Date
August 31, 2023
Pembrolizumab
The dose of pembrolizumab in this trial is 200 mg Q3W.
Cisplatin
25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
Gemcitabine
1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz-University Medical Center, Mainz
Universitaetsklinikum Leipzig UCCL-Krebszentrum, Leipzig
Vall d'Hebron Institut Oncologia, Barcelona
Hospital Universitario 12 De Octubre, Madrid
University College London Hospitals NHS Foundation Trust - University College Hospital, London
The Christie NHS Foundation Trust, Manchester
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK